Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Emergent BioSolutions (NYSE:EBS) has secured a $30 million contract modification from BARDA to supply CYFENDUS®, their FDA-approved two-dose anthrax vaccine. The deliveries are scheduled between late 2025 and March 2026.
This follows a previous $50 million contract modification from December 2024. CYFENDUS®, approved by the FDA in July 2023, is designed for post-exposure prophylaxis use in individuals aged 18-65 when administered with recommended antibacterial drugs. The vaccine addresses anthrax, which is classified as a Tier 1 biological threat due to its potential use in bioterrorism.
Emergent BioSolutions (NYSE:EBS) ha ottenuto una modifica contrattuale da 30 milioni di dollari da BARDA per la fornitura di CYFENDUS®, il loro vaccino anticarbuncolo approvato dalla FDA e somministrato in due dosi. Le consegne sono previste tra la fine del 2025 e marzo 2026.
La modifica si aggiunge a una precedente modifica contrattuale da 50 milioni di dollari di dicembre 2024. CYFENDUS®, approvato dalla FDA nel luglio 2023, è indicato per la profilassi post‑esposizione negli adulti di età compresa tra 18 e 65 anni quando somministrato insieme agli antibiotici raccomandati. Il vaccino mira a contrastare l’antrace, classificato come una minaccia biologica di livello 1 per il suo potenziale uso in attacchi bioterroristici.
Emergent BioSolutions (NYSE:EBS) ha asegurado una modificación contractual de 30 millones de dólares por parte de BARDA para suministrar CYFENDUS®, su vacuna contra el ántrax aprobada por la FDA y de dos dosis. Las entregas están programadas entre finales de 2025 y marzo de 2026.
Esto sigue a una anterior modificación contractual de 50 millones de dólares de diciembre de 2024. CYFENDUS®, aprobada por la FDA en julio de 2023, está indicada para profilaxis post‑exposición en personas de 18 a 65 años cuando se administra junto con los antibióticos recomendados. La vacuna se dirige al ántrax, clasificado como una amenaza biológica de Nivel 1 por su posible uso en bioterrorismo.
Emergent BioSolutions (NYSE:EBS)가 BARDA로부터 CYFENDUS® 공급을 위한 3,000만 달러 규모의 계약 변경을 확보했습니다. CYFENDUS®는 FDA 승인 2회 접종식 탄저 백신이며, 배송은 2025년 말부터 2026년 3월 사이에 예정되어 있습니다.
이번 계약은 2024년 12월의 5,000만 달러 계약 변경에 따른 추가 조치입니다. CYFENDUS®는 2023년 7월 FDA 승인을 받았고, 권장 항생제와 함께 투여할 경우 18-65세 성인의 노출 후 예방(prophylaxis)에 사용됩니다. 이 백신은 생물테러에 악용될 수 있어 1급 생물학적 위협(Tier 1)으로 분류되는 탄저를 대상으로 합니다.
Emergent BioSolutions (NYSE:EBS) a obtenu une modification de contrat de 30 millions de dollars de la part de BARDA pour fournir CYFENDUS®, son vaccin contre l’anthrax approuvé par la FDA en deux doses. Les livraisons sont prévues entre la fin 2025 et mars 2026.
Cette modification fait suite à une précédente modification de contrat de 50 millions de dollars datant de décembre 2024. CYFENDUS®, approuvé par la FDA en juillet 2023, est destiné à la prophylaxie post‑exposition chez les personnes de 18 à 65 ans lorsqu’il est administré avec les antibiotiques recommandés. Le vaccin cible l’anthrax, classé comme une menace biologique de niveau 1 en raison de son potentiel d’utilisation en bioterrorisme.
Emergent BioSolutions (NYSE:EBS) hat eine Vertragsänderung über 30 Millionen US-Dollar von BARDA erhalten, um CYFENDUS® zu liefern, ihren von der FDA zugelassenen Zwei-Dosen-Anthrax-Impfstoff. Die Lieferungen sind zwischen Ende 2025 und März 2026 geplant.
Dies folgt auf eine frühere Vertragsänderung über 50 Millionen US-Dollar aus dem Dezember 2024. CYFENDUS®, im Juli 2023 von der FDA zugelassen, ist für die Post‑Expositions‑Prophylaxe bei Personen im Alter von 18–65 Jahren bestimmt, wenn es zusammen mit den empfohlenen Antibiotika verabreicht wird. Der Impfstoff richtet sich gegen Milzbrand, der wegen seines Potenzials für Bioterrorismus als Tier‑1‑biologische Bedrohung eingestuft ist.
- New $30 million contract modification from BARDA for CYFENDUS® supply
- Follows previous $50 million contract modification from December 2024
- U.S.-based supply chain enhances strategic positioning for government contracts
- Addresses critical national security needs with FDA-approved product
- None.
Insights
Emergent secures $30M government contract for anthrax vaccine, bolstering revenue stream and reinforcing position in biodefense sector.
The
The timing of deliveries is particularly favorable for near-term financials, with shipments beginning this calendar year and completing by March 2026. This provides Emergent with a predictable revenue stream over the next several quarters, which is especially valuable for biodefense contractors who often face lumpy procurement cycles.
Strategically, this contract reinforces Emergent's position in the medical countermeasures market, specifically for protection against anthrax, which remains classified as a Tier 1 biological threat. The U.S.-based supply chain highlighted in the release carries dual significance: it aligns with national security priorities regarding domestic production capabilities for critical medical countermeasures and shields the company from international supply chain disruptions.
This contract also suggests the government's commitment to maintaining readiness against non-pandemic biological threats, even as much public attention has shifted elsewhere. The continued investment in anthrax countermeasures indicates BARDA is maintaining a diversified approach to biodefense preparedness, which benefits specialized suppliers like Emergent.
For investors, this procurement represents not just immediate revenue but validation of Emergent's continued relevance in the biodefense sector, where government relationships and contracting track record are crucial competitive advantages that create barriers to entry for potential competitors.
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a
"This new contract modification is the next step in our ongoing engagement with the U.S. government, with the shared goal to help ensure medical countermeasures, like CYFENDUS® vaccine, are readily available to safeguard civilian populations against the potential threat of anthrax,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “We're proud to leverage a U.S.-based supply chain for our anthrax vaccines, as we believe this is critical to Emergent’s leadership and continued support of the U.S. government’s national security priorities.”
Anthrax is a Tier 1 biological threat due to its potential to be used for a bioterrorist incident and threat to public health and national security. CYFENDUS® vaccine was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs.
This follows a previously announced contract modification of
About CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Indication
CYFENDUS® (Anthrax Vaccine Absorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs. The efficacy of CYFENDUS® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.
Important Safety Information
Contraindication: Do not administer CYFENDUS® to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) following a previous dose of CYFENDUS®, BioThrax® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS®) or any component of the vaccine.
Warnings and Precautions: Management of Acute Allergic Reactions: Appropriate medical treatment must be available to manage possible anaphylactic reactions following administration of CYFENDUS®. Pregnancy: CYFENDUS® can cause fetal harm when administered to a pregnant individual. In an observational study, there were more birth defects in infants born to individuals vaccinated with BioThrax® (a licensed anthrax vaccine with the same active ingredient as CYFENDUS®) in the first trimester compared to infants born to individuals vaccinated post pregnancy or individuals never vaccinated with BioThrax®.
Adverse Reactions: The most common (≥
To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-800-768-2304 or medicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
Please see the Prescribing Information for CYFENDUS® for full safety information.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the expected timing for delivery of the CYFENDUS® vaccine and Emergent’s ability to increase inventories of CYFENDUS® vaccine to meet requested levels within specified time frames, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
What is the value of Emergent BioSolutions' (EBS) new BARDA contract modification for CYFENDUS®?
When was CYFENDUS® approved by the FDA and what is it used for?
How much has BARDA contracted with Emergent BioSolutions (EBS) for CYFENDUS® since December 2024?
Why is Emergent BioSolutions' CYFENDUS® vaccine important for national security?
What is the delivery timeline for the new $30 million CYFENDUS® contract?
